Concord Biotech Acquires 100% Stake in Celliimune Biotech
Concord Biotech Limited announced the completion of an acquisition of Celliimune Biotech Private Limited on April 2, 2026. The acquisition, completed on an arm’s length basis, will see Concord Biotech advance research in DNA engineering for cancer therapeutics and develop innovative alternatives to conventional chemotherapy.Celliimune Biotech Private Limited was incorporated on January 15, 2025, in India. The company’s authorized share capital is Rs. 12,00,000 divided into 12,00,000 equity shares of Rs. 10 each, with an issued share capital of Rs. 66,00,000 divided into 6,60,000 equity shares of Rs. 10 each. Celliimune Biotech has had Nil Turnover.
Concord Biotech acquired 100% equity in Celliimune Biotech for a cash consideration of Rs. 66,00,000. As a result of the acquisition, Celliimune Biotech has become a wholly owned subsidiary of Concord Biotech Limited. Prior to this acquisition, the Promoter / Promoter group held majority shareholding in the Company, and Mr. Ankur Vaid and Ms. Sonal Kumra serve as Directors of the Company.
Celliimune Biotech specializes in the discovery, development, and commercialization of novel cell and gene therapy solutions.
| Particulars | Details | |
|---|---|---|
| c) | Industry to which the entity being acquired belongs | Biopharmaceutical Industry |
| d) | Objects and impact of acquisition | To advance pioneering research in DNA engineering for cancer therapeutics and to develop innovative alternatives to conventional chemotherapy. The acquisition is going to help in innovating new therapy for treatment of cancer. |
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.